Alliancebernstein L.P. Keros Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

$275 Billion
Q1 2024

A detailed history of Alliancebernstein L.P. transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 91,858 shares of KROS stock, worth $4.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

91,858

Previous 21,120 334.93%

Holding current value

$4.2 Million

Previous $839,000 624.67%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$41.26 - $70.48 $2.92 Million - $4.99 Million	70,738 Added 334.93%	91,858 $6.08 Million
Q2 2023 Aug 15, 2023	BUY	$37.26 - $51.01 $179,593 - $245,868	4,820 Added 29.57%	21,120 $848,000
Q4 2022 Feb 14, 2023	BUY	$39.45 - $51.77 $55,230 - $72,478	1,400 Added 9.4%	16,300 $782,000
Q3 2022 Nov 15, 2022	SELL	$27.8 - $40.12 $2,780 - $4,011	-100 Reduced 0.67%	14,900 $561,000
Q2 2022 Aug 15, 2022	BUY	$26.03 - $67.04 $72,884 - $187,712	2,800 Added 22.95%	15,000 $414,000

Q4 2021 Feb 14, 2022	SELL	$36.95 - $62.89 $107,155 - $182,381	-2,900 Reduced 19.21%	12,200 $714,000
Q2 2021 Jul 30, 2021	BUY	$42.4 - $70.11 $63,600 - $105,165	1,500 Added 11.03%	15,100 $641,000
Q1 2021 May 06, 2021	SELL	$54.0 - $75.28 $48,600 - $67,752	-900 Reduced 6.21%	13,600 $837,000
Q4 2020 Feb 08, 2021	BUY	$36.0 - $82.74 $270,000 - $620,550	7,500 Added 107.14%	14,500 $1.02 Million
Q3 2020 Nov 12, 2020	BUY	$27.04 - $62.21 $24,336 - $55,989	900 Added 14.75%	7,000 $270,000
Q2 2020 Aug 13, 2020	BUY	$20.08 - $40.39 $122,487 - $246,379	6,100 New	6,100 $229,000

Others Institutions Holding KROS

# of Institutions

153

Shares Held

26.7M

Call Options Held

47.6K

Put Options Held

34.5K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.18B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Keros Therapeutics, Inc. Transaction History